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The conceptualization of the placebo phenomenon has changed. Previously placebo was 
seen as an inactive agent, but today placebo effects are viewed as related to patients’ percep-
tion of a treatment. During the last decades, the mechanisms underlying placebo analgesia 
effects have been specified and it has been shown that patients’ perception of a treatment 
is influenced by previous experiences, the patient-practitioner relationship as well as ex-
pectations and emotions. These factors are, in turn, associated with altered brain activa-
tion and release of endogenous opioids, thereby demonstrating that placebo analgesia has a 
psycho-neurobiological basis. The placebo effect has primarily been investigated in relation 
to healthy volunteers, but here we review literature on placebo mechanisms in relation to 
chronic pain states as this is important for an understanding of how placebo factors can be 
optimized in clinical practice. We outline some of the ethical discussions concerning the 
use of placebo in clinical practice and we illustrate how patients perception of a treatment 
contribute to the efficacy of active treatments, thereby showing how focus on patients per-
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ception of a treatment may help optimize the outcome of standard active pain treatments in 
ethically appropriate ways. 
Introduction
Traditionally, placebos have been seen as inactive agents used as control conditi-
ons for active agents under study in randomized clinical trials (Andersen 1997). 
During the last decades, however, the conceptualization of the placebo phenom-
enon has evolved and today the placebo effect is associated with subjects’ or pa-
tients’ perception of receiving a treatment (Price, Finniss & Benedetti 2008; Vase, 
Nørskov, Petersen & Price 2011; Vase, Riley & Price 2002). The psychosocial and 
neurobiological mechanisms underlying placebo analgesia effects in particular are 
being unraveled (Benedetti 2009; Bingel et al. 2006; Price, Finniss & Benedetti 2008; 
Wager et al. 2004) and, importantly, it has been shown that placebo components do 
not only contribute to the efficacy of inactive placebo agents but also to the effic-
acy of active pharmacological agents (Benedetti 2009; Benedetti & Amanzio 2011; 
Kam-Hansen et al. 2014; Kaptchuk et al. 2008; Klinger, Soost, Flor & Worm 2007; 
Petersen et al. 2012; Price et al. 2007; Schenk, Sprenger, Geuter & Büchel 2014; Vase, 
Robinson, Verne & Price 2003, 2005). Hence, by optimizing the placebo compo-
nents of active pain relieving treatments, it may be possible to enhance the overall 
treatment outcome. So far, placebo research has mostly involved healthy volun-
teers (Benedetti 2008; Price, Finniss & Benedetti 2008). However, in order to fully 
understand how placebo effects can be optimized in clinical practice, it is pivotal 
also to understand the mechanisms underlying placebo effects in chronic pain 
patients as placebo effects in healthy volunteers exposed to experimental pain and 
chronic pain patients may differ (Hyland 2001; Klinger & Flor 2013; Vase, Skyt, Pe-
tersen & Price 2014). This review will outline current knowledge of placebo effects 
in chronic pain states and discuss how placebo components of treatments can be 
optimized in clinical practice. Moreover, we will discuss ethical dilemmas related 
to the use of placebo effects in clinical practice and put forward ideas of how pla-
cebo components can be optimized in ethically appropriate ways. 
65Placebo effects in chronic pain conditions
Conceptualization of the placebo effect
Definitions
The word ‘placebo’ is derived from Latin and means ‘I want to please’ (Andersen 
1997). With the introduction of the randomized controlled trial (RCT), placebos 
became conceptualized as inert agents or sham treatments (e.g., sugar pill or sali-
ne injection) used as control conditions for active treatments under study in order 
to demonstrate the efficacy of new medications. 
In order to understand the current conceptualization of the placebo phenome-
na it is important to differentiate between the placebo effect, the placebo response 
and the natural history of a disease (see Figure 1). Pain, for example, fluctuates 
over time and the natural history of a migraine attack is likely to follow the curve 
in 1A, where pain reaches a maximum and vanishes by itself without a treatment. 
In RCTs, inactive placebo treatments are typically given when the pain intensity 
is high and the subsequent reduction in pain may be termed the placebo response 
(Kirsch 2013; Vase & Petersen 2013). However, it is important to be aware that since 
this placebo response is not controlled for the natural history of the pain, it is not 
possible to deduce whether the observed pain reduction is due to the treatment 
itself or to confounding factors like the natural history of the pain, regression to 
the mean or the like (see Figure 1B) (Benedetti 2009; Fields & Price 1997). In order 
to verify that the observed pain reduction is due to the placebo intervention, it 
is essential to control for the natural history of the pain and to calculate the pla-
cebo effect (see Figure 1C). This can be done by including a placebo-treated group/
condition and a no-treated group/condition and estimating the placebo effect as 
the difference in pain levels between the two groups/conditions. Hence, the main 
difference between the placebo response and the placebo effect is that the latter is 
controlled for confounding factors thereby making it is possible to conclude that 
the observed pain relief is due to the administered placebo treatment (Benedetti 
2009; Kirsch 2013; Vase & Petersen 2013).
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Figure 1. The development of pain is illustrated under three different conditions. A: No 
treatment control condition showing the natural history of the pain. B: Treatment with an 
inert placebo agent showing that the pain reduction following administration of an inert 
treatment may be due to the natural history of pain rather than to the treatment. C: No 
treatment (I), placebo treatment (II), and active treatment (III) allowing for a calculation 
of the placebo analgesia effect as the difference between the no treatment and the placebo 
treatment group/condition.
It is widely accepted that placebo effects are related to psychosocial factors sur-
rounding a treatment such as the verbal suggestions provided by practitioners 
and expectation about low pain levels (Benedetti 2009; Price, Finniss & Benedetti 
2008). Based on this knowledge, the placebo effect has been defined as the redu-
ction in a symptom as a result of factors related to the subject’s/patient’s percep-
tion of the therapeutic intervention (Vase, Riley & Price 2002). In addition, some 
authors have even suggested that the phrase ‘placebo effect’ should be replaced 
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by terms such as ‘meaning response’ (Moerman 2013), ‘context effect’ (Di Blasi & 
Kleijnen 2003) or ‘expectation effect’ (Kirsch 1999).
Current designs to investigate placebo effects
The change in the conceptualization of the placebo phenomena has led to advan-
ced ways of investigating placebo effects. In traditional studies of placebo effects, 
inactive placebo treatments are administered and researchers are interested in the 
difference in pain levels between placebo-treated and no-treated control groups/
conditions (Benedetti 2008, 2009; Price, Finniss & Benedetti 2008; Vase & Petersen 
2013).  
As researchers became more interested in the psychosocial factors related to 
placebo effects, designs that allowed for manipulation of these factors evolved. 
One such design is the balanced placebo design, which is a 2 by 2 design, where 
administration of an inactive placebo treatment and an active treatment are balan-
ced with correct and false information about the treatment (see Figure 2) (Kirsch & 
Weixel 1988; Ross, Krugman, Lyerly & Clyde 1962). By using this design, it is pos-
sible to evaluate drug effects (given active agent, told placebo), placebo effects (gi-
ven placebo, told active agent), and total treatment effects including active drugs 
and placebo components (given active agent, told active agent). Also, a baseline 
condition is included (given placebo, told placebo) against which active and pla-
cebo treatments can be compared. 
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Figure 2. The balanced placebo design. Administration of inactive placebo treatments and 
active drug treatments are balanced with correct and false information about the treat-
ment. The design allow for calculation of the total effect of the active drug plus the placebo 
effect (get active, told active), the placebo effect (get placebo, told active), and the drug 
effect (get active, told placebo). The design also includes a control condition (get placebo, 
told placebo) against which the effect of the drug, the placebo and a combination of drug 
and placebo can be compared. 
The balanced placebo design is interesting because it reveals how psychosocial 
factors, such as the verbal information given by the practitioner, can influence 
the efficacy of both active and inactive treatments. More recently, the balanced 
placebo design has been utilized to specify the relative contribution of the drug ef-
fect and the placebo effect to an overall treatment outcome, thereby furthering the 
understanding of possible interactions between placebo and drug effects (Atlas et 
al. 2012; Lund et al. 2014; Schenk, Sprenger, Geuter & Büchel 2014).
The open/hidden design is another placebo design, allowing for examination 
of psychosocial placebo components of a treatment without administration of in-
active placebo treatments (see Figure 3) (Amanzio, Pollo, Maggi & Benedetti 2001; 
Benedetti, Carlino & Pollo 2011; Levine & Gordon 1984; Levine, Gordon & Fields 
1978). This design focuses on patients’ perception of a treatment and only active 
agents are given. In one condition, a practitioner administers an active treatment 
in full view of the patients and gives verbal information about pain relief (open 
condition) (see Figure 3A). In another condition, the same active agent is given 
without the patients’ knowledge, e.g. via a computer-controlled infusion pump 
(hidden condition) (see Figure 3B).  Only in the open condition, patients perceive 
the treatment and thereby form expectations about pain relief, and the placebo ef-
fect is calculated as the difference in pain levels between the open and the hidden 
administration, controlled for natural history of the pain. Hence, the open/hidden 
design allow for a calculation of the pharmacological component of a treatment 
(hidden condition) and the psychosocial placebo component of the treatment 
(open minus hidden condition), thereby making it possible to investigate how 
each of these factors contribute to the overall treatment effect. This design relates 
to the more modern view of placebo effects. Given that no inactive treatments are 
given and that patients’ perception is manipulated instead, this design represents 
an ethically acceptable investigation of the placebo effect and thereby illustrates 
how psychosocial placebo components can be applied in clinical practice.
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Figure 3. The open/hidden placebo design. The same active treatment is given in an open 
and a hidden manner. In the open condition, the treatment is given by a practitioner in 
full view of the patient (A), while in the hidden condition, the active treatment is given 
without the patient’s knowledge, e.g. via a computer-controlled infusion pump (B). The 
placebo effect is calculated as the difference in pain levels between the open and the hidden 
condition, controlled for natural history of the pain
Treatment history
Placebo analgesia effects appear to be critically influenced by prior treatment ex-
periences in either negative or positive ways. This has been well documented in 
healthy volunteers and it also seems to apply chronic pain conditions (Colloca et 
al. 2010; Kessner et al. 2013b; Laska & Sunshine 1973; Voudouris, Peck & Coleman 
1989, 1990). Kessner & colleagues (2013b) conducted a study of healthy volunte-
ers where the influence of previous treatments was directly investigated. In this 
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study, 39 healthy participants were exposed to painful heat stimuli at the left fo-
rearm. The pain corresponded to an individual pain level of 80 on a 0-100 visual 
analogue scale. The study took place over three days and on each day an inert 
analgesic treatment was administered; nevertheless, participants were told that 
an active analgesic was given. On the first two test days, when the (inert) analgesic 
treatment was administered, the heat pain intensity was surreptitiously decre-
ased from 80 to 20 in half of the participants to give the participants an experience 
of pain relief (positive treatment history group), whereas it remained stable in the 
other half of the participants (negative treatment history group). Hence, partici-
pants in the positive group were conditioned to experience a pain relieving effect 
of the treatment, whereas the negative group was not. On the third test day, a new 
inert analgesic was administered and the heat pain intensity was surreptitiously 
decreased from 80 to 50 in all participants. Interestingly, the effect of the inert 
analgesic was significantly higher in the group who had previously experienced 
a pain relieving effect than in the group who had not. This study indicates that 
negative and positive treatment experiences can influence later treatments. 
The importance of prior treatment experiences have not been directly investi-
gated in chronic pain patients. However, a salient study by Laska & Sunshine 
(1973) indicates that treatment history may indeed influence clinical pain treat-
ment. In this study, a mixed group of pain patients received two analgesic treat-
ments, the second always being a placebo treatment. The first treatment consisted 
of either the active analgesics propoxyphene HCL or propoxyphene napsylate 
administered in three graded doses or a placebo treatment. Hence, the study in-
cluded seven groups of patients with twelve to twenty patients in each group. 
Results showed a convincing dose-response relationship between the dose of the 
first analgesic treatment and the subsequent placebo treatment so that the placebo 
given as a second treatment acted as an effective analgesic when it followed an ac-
tive analgesic, whereas the placebo following another placebo treatment only had 
a small analgesic effect. Although this clinical trial did not control for patients’ 
natural pain history, it supports the involvement of learning or conditioning pro-
cesses in placebo effects in chronic pain patients. 
Taken together, these data suggest that treatment of chronic pain is affected by 
prior treatment history. This may have considerable implications for clinical prac-
tice because chronic pain patients often have a long history of treatment failures 
(Kessner et al. 2013b; Klinger & Flor 2013). Clinicians may actively try to reduce 
the influence of patients’ negative treatment experiences by creating new and po-
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sitive associations between treatment effects and pain medication (Klinger & Flor 
2013). 
The patient-practitioner relationship 
The specific relationship between a patient and a practitioner may also affect pla-
cebo effects in chronic pain states. In a study by Kaptchuk and colleagues (2008), 
262 patients suffering from Irritable Bowel Syndrome (IBS) were divided into 
three different treatment groups. The first group received no treatment (control). 
The second group received three weeks of a so-called ‘limited placebo acupunctu-
re’, whereas the third group received so-called ‘augmented placebo acupuncture’. 
The placebo acupuncture was the same in group two and three, and only factors 
related to the psychosocial context differed. In the second group (limited placebo 
acupuncture), the patient-practitioner relationship was established in less than five 
minutes at the initial visit. In this setup, the doctor introduced himself and then 
informed the patient that the study was scientific and the doctor was instructed 
not to converse with the patients. Contrary to this, in the third group (augmented 
placebo acupuncture) the patient-practitioner relationship was established during 
a 45-minute initial visit and the practitioner acted warmly, friendly, and emphati-
cally and communicated positive expectations about the treatment. The aim of the 
latter approach was to obtain a so-called optimal patient-practitioner relationship. 
The treatment outcome was measured using four different scales (global impro-
vement scale, adequate relief of symptoms, symptom severity score, and quality 
of life) and for all outcome measures the same symptom progression appeared. 
The smallest symptom reduction followed the control group (no treatment). The 
limited placebo acupuncture was more effective than the control; however, the 
effect of the augmented placebo acupuncture was significantly larger than the 
limited placebo acupuncture across all outcome measures. These results indicate 
that the type of patient-practitioner relationship influences clinical outcome. 
To better understand the association between placebo effects and the patient-
practitioner relationship, the research group further elaborated the influence of 
specific patients characteristics (i.e., personality traits and demographics), practi-
tioner effects (i.e., a combined score based on the four IBS scales cf. above), and the 
nature of the interpersonal interaction (i.e., recorded on videotapes and rated via 
the Psychotherapy Process Q-set (PQS) by independent clinical judges) (Kelley et 
al. 2009). Prior to the study, a prototype of an ideal healthcare encounter was con-
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structed against which the patient-practitioner interaction in the study could be 
compared (for further information see Kelley et al. 2009). The results showed that 
patient characteristics like extraversion, agreeableness, openness, and female gen-
der were associated with the placebo effect. Also, there were significant differen-
ces in outcomes between different practitioners, indicating that practitioners can 
have relatively large differential effects on the placebo effect, even when treatment 
is highly standardized. Importantly, the study revealed that the patient-practi-
tioner relationship in the augmented placebo group was successful and highly 
correlated with the prototype of the ideal healthcare encounter. In contrast, the 
patient-practitioner relationship was only moderately correlated with the ideal he-
althcare prototype in the limited placebo group, thereby indicating that the sharp 
difference in the nature of the patient-practitioner interaction between the limited 
and augmented placebo groups is likely to be responsible for the differences in 
treatment outcome.  
Another interesting study has tested whether the placebo effect can be pharma-
cologically boosted by the neuropeptide oxytocin in healthy volunteers (Kessner 
et al. 2013a). Oxytocin is involved in processes such as empathy and trust, which 
are key elements of the patient-practitioner relationship. The study compared the 
placebo effect across participants receiving oxytocin and participants receiving 
inert saline (control). An inert analgesic treatment was used to induce placebo 
effects. Data revealed that the placebo response was significantly higher in the 
oxytocin group than in the control group. Based on the effect on empathy and 
trust, it was proposed that the administration of oxytocin increased participants’ 
believability of the instructions of the doctor and thereby enhanced the placebo 
effect. This study supports the notion that factors related to the patient-practitio-
ner relationship such as empathy, trust and warmth are important components of 
placebo responsiveness.
Based on the hypothesis that reciprocal interactions between patient and doctor 
may be involved in placebo effects (in addition to the patient perspective alone), 
one study has examined the activation of the doctor’s brain while treating pain 
patients (Jensen et al. 2014). Results revealed that brain regions associated with 
expectancy for pain relief such as the right ventrolateral and dorsolateral prefron-
tal cortices was activated in doctors while treating patients. Moreover, the doctor’s 
ability to take the patient’s perspective correlated with activity in the rostral ante-
rior cingulate cortex, a region that has been associated with reward and subjective 
value. This study suggests that placebo analgesia effects may be dependent on the 
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perspective of both the patient and the doctor and, consequently, emphasizes the 
importance of the reciprocal relationship between the doctor and the patient.
Overall, data suggest that an empathic, warm and trusting patient-practitio-
ner relationship is an important factor in establishing placebo effects and posi-
tive therapeutic outcome leading to pain relief. Thus, based on these findings it is 
recommended that practitioners focus on the patient-practitioner relationship in 
clinical practice in order to improve treatment outcomes. 
Verbal suggestions
The verbal suggestions that doctors provide to patients are central to placebo ef-
fects. This has directly been shown in two studies of Irritable Bowel Syndrome 
(IBS) patients performed by Vase and colleagues (2003) and Verne and colleagues 
(2003). In both studies, patients went through similar placebo treatments, howe-
ver, the studies varied according to the verbal suggestions given. The study by 
Vase and colleagues was conducted as a placebo mechanism study and patients 
were told that ‘the agent you have just been given is known to significantly reduce 
pain in some patients’. Contrary to this, the study by Verne and colleagues was 
designed as a clinical trial where patients via the informed consent were told ‘you 
may receive an active pain reducing medication or an inert placebo agent’. Results 
from the two studies showed that the placebo mechanism study with enhanced 
verbal suggestions induced markedly larger placebo analgesia effects than the cli-
nically designed study. In fact, the magnitude of the placebo analgesia was so 
high that there was no significant difference between the placebo and the active 
treatment, indicating that by adding a verbal suggestion for pain relief it is pos-
sible to increase the magnitude of placebo analgesia to a level that matches that of 
an active agent (Vase, Robinson, Verne & Price 2003). 
Recently, a landmark study by Kam-Hansen and colleagues (2014) has further 
elaborated the verbal suggestions given for pain relief in relation to both a placebo 
treatment and an active treatment. This study used an extended, balanced placebo 
design, in which active (Maxalt, 10-mg rizatriptan) and inactive placebo pills were 
given with three types of information (negative = told placebo, uncertain = told 
placebo or active agent, positive = told active). Hence, 66 patients with episodic 
migraine were tested in seven different sessions. The primary outcome measure 
was the change in headache between the baseline pain score reported 30 minutes 
after the onset of headache and the pain score recorded two hours later. Several 
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interesting results can be derived from this study. First, the outcome of both inert 
placebo and active drug treatments improved with stronger verbal suggestions 
about treatment effects, i.e., effects of both inert placebo and active medication 
were highest when treatment was labeled as active medication or had uncertain 
labeling, and lowest when treatments were labeled as placebo. Second, the effect 
of the mislabeled active drug (given active agent, told placebo) was similar to the 
mislabeled inert placebo (given placebo, told active agent). Third, relative to no 
treatment, the placebo, under each information condition, accounted for more 
than 50 percent of the drug effect. These data emphasize that the efficacy of both 
active drugs and inert placebos may indeed be modulated by verbal information 
about treatment effects. 
The critical influence of verbal suggestions has been supported by studies using 
the open/hidden design that resembles clinical practice to a great extent (Petersen 
et al. 2012, 2014). In two similar studies, neuropathic pain patients received open 
and hidden administrations of the active pain relieving agent lidocaine. In the 
open condition, lidocaine was administered in full view of the patient and follo-
wed by the verbal suggestion that ‘the agent you have just been given is known to 
powerfully reduce pain in some patients’. In the hidden condition, lidocaine was 
administered without the patient’s knowledge and without any verbal suggesti-
ons about pain relief. Importantly, the patients received the same pharmacological 
agent in the open and hidden conditions and only the psychosocial placebo com-
ponents differed. Results from the studies showed that significant placebo effects 
can be obtained in spontaneous neuropathic pain as well as in different types of 
evoked pain such as area of hyperalgesia, pinprick hyperalgesia, and wind-up like 
pain. Overall, these studies support the notion that adding a verbal suggestion 
for pain relief may increase the effect of an active pharmacological pain relieving 
treatment. 
In general, studies giving positive and certain verbal suggestions for pain relief 
find larger magnitudes of placebo effects compared to studies with  uncertain or 
negative verbal suggestions, proposing that placebo effects can profitably be op-
timized in clinical practice by shaping verbal suggestions in specific ways (Kapt-
chuk et al. 2008; Price et al. 2007). Hence, practitioners should be careful when in-
forming patients about treatment effects and try to point out positive and realistic 
expectations, yet without deceiving or misleading patients. 
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Expectations and emotional feelings 
Previous treatment experiences, the patient-practitioner relationship and the 
verbal suggestions given for pain relief are likely to influence patients’ expectati-
ons about pain relief. Several studies have shown that expectations about low pain 
levels contribute to placebo effects in both healthy volunteers and in chronic pain 
patients (Bingel et al. 2011; Kirsch 1999; Price et al. 1999; Vase, Robinson, Verne 
& Price 2003; 2005). Measures of expected pain levels are typically assessed by 
asking patients ‘what do you expect your pain level to be?’ right after a treatment 
has been administered and before it has taken effect. Patients then indicate their 
expected pain level on a visual analogue scale ranging from ‘no pain’ to the ‘worst 
pain imaginable’ (Petersen et al. 2012; Price et al. 1999; Vase, Robinson, Verne & 
Price 2003). In a study including patients suffering from IBS, expected pain levels 
along with desire for pain relief accounted for up to 81 percent of the variance in 
pain levels following both inactive placebo treatments and active lidocaine admi-
nistrations (Vase, Robinson, Verne & Price 2003). A second study supported the 
result and showed that expected pain levels along with desire for pain relief and 
anxiety levels accounted for up to 73 percent of the variance in pain levels follo-
wing both placebo and active treatments of IBS patients (Vase, Robinson, Verne & 
Price 2005). In both studies, ratings of expected pain levels were the only unique 
predictor for the variance in pain levels. Therefore, optimizing patients’ expec-
tations about treatment effects via for example verbal suggestions may lead to 
improved treatment outcomes in medical practice.
Research including both healthy volunteers and chronic pain patients indicate 
that positive and negative emotions are also involved in placebo effects (Flaten et 
al. 2006; Flaten, Aslaksen, Lyby & Bjørkedal 2011; Petersen et al. 2012, 2014; Vase, 
Robinson, Verne & Price 2005). A number of studies have, for example, shown that 
high levels of negative emotions like stress and fear reduce or abolish placebo ef-
fects (Lyby, Aslaksen & Flaten 2010; Lyby, Forsberg, Åsli & Flaten 2012). Lyby and 
colleagues (2012) has examined the effect of fear on placebo analgesia in healthy 
volunteers exposed to experimental pain. In a within-subject design, participants 
were given placebo pills followed by the information that they contained a po-
werful painkiller (placebo condition). In order to induce fear, participants were 
shortly after told that they would receive electric shock (placebo plus fear condi-
tion). The placebo effects in the placebo plus fear condition was compared to the 
placebo effect in the placebo condition alone, and to a natural history condition 
without any placebo or fear manipulations. The study revealed that induced fear 
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abolished the placebo effect. In addition, the abolished placebo effect was most 
pronounced in participants who reported the highest level of fear.  
Two subsequent studies have examined the involvement of negative as well as 
positive emotions in placebo effects in neuropathic pain patients (Petersen et al. 
2012, 2014). Both studies used open and hidden administrations of lidocaine to 
induce placebo effects. In the first study, the Positive Affect Negative Affect Sche-
dule (PANAS), listing twenty predefined emotions divided into a positive and a 
negative affect scale, was used to assess the contribution of emotions in placebo 
effects (Petersen et al. 2012). Results from the study showed that a low score on 
the negative affect scale was associated with placebo analgesia, while the positive 
affect scale was not associated with placebo analgesia. The second study asses-
sed emotions during the placebo intervention by directly asking patients about 
their experiences immediately after the placebo treatment was administered and 
before it had taken effect (Petersen et al. 2014). Patients were asked to quantitati-
vely rate their expected pain levels on a mechanical visual analogue scale and to 
qualitatively describe their emotions in a few words. Following the open condi-
tion, patients reported higher intensities of positive than negative emotions. These 
findings suggest that high levels of positive emotions and low levels of negative 
emotions are related to the pain experience during placebo interventions. This 
relationship is also consistent with research on clinical pain, which shows that ne-
gative emotions increase painful sensations, while positive emotions reduce pain-
ful sensations (Keefe et al. 2001; Rhudy et al. 2008). The study further indicated 
that patients’ expectations are closely related to their emotions as illustrated by a 
patient saying ‘I am hoping that the cream will bring relief’. 
Overall, when treating chronic pain patients it may be important to remember 
that expectations co-exist with emotions. Consequently, practitioners who try to 
optimize treatment expectations may also benefit from paying attention to pa-
tients’ emotions with the aim of preventing negative emotions and promoting 
positive emotions (Flaten, Aslaksen & Lyby 2013).
Neurobiological basis for placebo analgesia in chronic 
pain disorders 
Whether placebo effects represent neurobiological phenomena rather than simple 
response bias has been extensively debated (Benedetti & Frisaldi 2013; Eippert & 
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Büchel 2013; Hróbjartsson & Gøtzsche 2001, 2004; Pecina & Zubieta 2013; Vase, Ri-
ley & Price 2002; Vase, Petersen, Riley & Price 2009). Brain imaging performed in 
healthy volunteers has shown that placebo analgesia is associated with increased 
activity in cortical areas as the dorsolateral prefrontal cortex (DLPFC) and orbito-
frontal cortex (OFC), which may be associated with expectations of pain relief 
(Wager et al. 2004), as well as in the rostral anterior cingulate cortex (rACC) and 
the periaqueductal gray (PAG) (Amanzio et al. 2013; Atlas & Wager 2012; Bingel 
et al. 2006; Kong et al. 2006; Petrovic, Kalso, Petersson & Ingvar 2002). In addition, 
placebo analgesia is related to decreased neural activity in areas of the so-called 
pain matrix like the thalamus, the insula, and the anterior cingulate cortex (Wa-
ger et al. 2004). Hence, placebo analgesia involves top-down modulation of pain 
and it has even been shown to inhibit pain-related activity at levels of the spinal 
cord (Eippert, Finsterbusch, Bingel & Büchel 2009). One functional neuroimaging 
study has demonstrated that placebo analgesia in IBS patients is also associated 
with reductions in neural activity in areas of the pain matrix (thalamus, insula, 
somatosensory cortices, and anterior cingulate cortex) (Price et al. 2007). Seve-
ral pharmacological studies have shown that the opioid antagonist, naloxone, can 
block placebo analgesia in healthy volunteers, suggesting that the endogenous 
opioid system is involved in these placebo effects (Amanzio & Benedetti 1999; Be-
nedetti 1996; Gracely, Dubner, Wolskee & Deeter 1983; Levine, Gordon & Fields 
1978; Zubieta et al. 2005). Contrary to this, naloxone has not been able to block 
placebo analgesia in chronic pain states (Kupers et al. 2007; Vase, Robinson, Verne 
& Price 2005). Recently, it was shown that non-opioid mediated placebo analgesia 
effects in healthy volunteers can be blocked by the cannabinoid antagonist rimo-
nabant (Benedetti, Amanzio, Rosato & Blanchard 2011; Benedetti et al. 2013). In 
addition, studies employing functional molecular imaging have observed incre-
ased dopamine release in areas such as the nucleus accumbens, typically related 
to processes of reward and motivation, during placebo administrations in healthy 
volunteers, which is likely to be related to the anticipation of a treatment effect 
(Scott et al. 2007, 2008). So far the endocannabinoid and the dopaminergic systems 
have not been examined in relation to chronic pain states. 
Ethical considerations 
Although deceptive administration of inactive placebo pills may lead to pain re-
lief as shown above, this is considered unethical and is not recommended in cli-
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nical practice (Price 2005). If patients find out that they have been deceived, this 
is likely to ruin the patient-practitioner relationship and it may undermine the 
efficacy of future treatments. However, surveys show that a large proportion of 
practitioners do prescribe placebos understood as inactive treatments (pure place-
bos) or treatments that do not have any known effect on the condition for which it 
is given (impure placebos) (Fässler, Meissner, Schneider & Linde 2010; Hróbjarts-
son & Norup 2003; Miller & Colloca 2009; Tilburt et al. 2008). For instance, a que-
stionnaire study of Danish practitioners showed that during the previous year 86 
percent of general practitioners, 54 percent of hospital-based physicians, and 41 
percent of private specialists had used impure placebo interventions where an 
active medication was given although the pharmacological effect on the disease 
is known to be negligible (Hróbjartsson & Norup 2003). Similar data has been 
found in the United States, Europe and Israel (Kermen, Hickner, Brody & Hasham 
2010; Linde et al. 2014; Nitzan & Lichtenberg 2004; Tilburt et al. 2008). Notably, 
clinicians in the study of Danish practitioners most often explained the impure 
placebo interventions in terms of ‘following the wish of the patient and avoid con-
flict’, which questions whether the administration of placebo agents take place in 
a good patient-practitioner relationship and thereby whether it will in fact lead to 
a placebo effect. Recently, patients have been asked directly about their attitude 
toward inactive placebo administration and it was actually found that many pa-
tients are open to the idea of inactive placebo treatments (Hull et al. 2013). A study 
including patients with a chronic health problem found that most patients (up to 
84 percent) judged that it was acceptable for doctors to recommend placebo treat-
ment if they for instance thought that the treatment would benefit and not harm 
the patient (ibid.). Only 21.9 percent judged that it was never acceptable for doctors 
to use placebo treatments. Nevertheless, patients valued honesty and trust, which 
was illustrated by patients saying that doctors should be honest about an inter-
vention being a placebo intervention when patients ask specific questions about 
the treatment.
It has been a general assumption that inactive placebo agents are only effective 
if they are given deceptively. Recently, however, this assumption has been chal-
lenged. In a couple of studies, patients have been given so-called open-label pla-
cebo, i.e., patients are specifically informed that they receive inactive placebo tre-
atments and, surprisingly, these studies yield large placebo effects. In a landmark 
study by Kaptchuk and colleagues (2010), 80 IBS patients were divided into two 
groups, one group received inert placebo pills in an open manner, and the other 
group received no treatment (control group). The placebo group was given pla-
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cebo pills in a typical medicine bottle labelled ‘placebo pills’ – ‘take two pills twice 
daily’ and told that ‘placebo pills, something like sugar pills, have been shown in 
rigorous clinical testing to produce significant mind-body self-healing processes’. 
Patients in the control group were not given any medication but were reminded 
of the importance of a control arm. Information in both the control and the pla-
cebo group was given in the context of a warm, supportive patient-practitioner 
relationship. Results showed that the placebo-treated patients improved signifi-
cantly more than the patients in the control group. This finding is supported by a 
study by Kam-Hansen and colleagues (2014), in which open-label administrations 
of inert placebos led to greater symptom reduction in migraine patients than in 
a no-treated control group. Overall, these studies indicate that openly admini-
stered inactive placebo treatments without deception can contribute to treatment 
outcomes, thereby furthering that the bare presence of psychosocial factors like 
a supportive patient-practitioner relationship and a specific treatment ritual can 
lead to clinically meaningful symptom improvements probably because patients 
expect an effect. Yet, although it is possible to administer inactive agents in ethical 
acceptable ways, it is generally recommended to administer active agents and at 
the same time pay attention to patients’ perception of the treatment.
As listed in the introduction, the placebo effect is seen as related to patients’ 
perception (Vase, Riley & Price 2002). Hence, the placebo components of a treat-
ment can be enhanced by focusing on patients’ perception of the treatment. This 
is elegantly shown in the described studies using the open/hidden placebo design, 
where patients who are told that an active treatment is given experience signifi-
cantly more pain relief than patients who are not told that an active treatment is 
administered (Petersen et al. 2012, 2014). Thus, by actively focusing on patients’ 
perception of the treatment, it may be possible to enhance the placebo component 
of the treatment and thereby the overall treatment outcome. At present, this ap-
pears to be the best way to optimize placebo factors in clinical practice. Recent cli-
nical trials have shown that pain patients who are treated by doctors scoring high 
on factors such as empathy and communication skills, experience better symptom 
improvement than patients treated by doctors not scoring high on these factors 
(Hojat et al. 2011; Kelley et al. 2014). Hence, these studies provide specific infor-
mation on how patients’ perception of a treatment may be optimized and thereby 
contribute to the efficacy of active treatments.     
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Awareness of placebo components is critical in clinical 
practice 
The finding that patients’ perception of a treatment contributes to the efficacy of 
both active and inactive treatments has led to new ways of integrating knowledge 
of placebo factors in clinical practice. The discussion is no longer whether inactive 
agents should be administered in ethically questionable ways, but rather how ac-
tive agents can be administered in a context that favors the patient’s perception of 
the treatment so the overall treatment efficacy can be enhanced (Benedetti 2009; 
Benedetti & Amanzio 2011; Kirsch 2013; Klinger & Flor 2013; Lichtenberg, Here-
sco-Levy & Nitzan 2004). In this article, we have primarily shown how previous 
experiences, the patient-practitioner relationship as well as expectations and emo-
tions may contribute to an enhanced treatment outcome.
Studies investigating how patients’ negative perception and expectations to-
wards treatment contribute to treatment outcomes are also emerging (Amanzio, 
Corazzini, Vase & Benedetti 2009; Bingel et al. 2011; Rief, Avorn & Barsky 2006). 
In a study by Bingel and colleagues (2011), the analgesic treatment remifentanil 
was administered under three information conditions (with no expectations of 
an analgesic, with expectancy of a positive analgesic, and with negative expec-
tancy of exacerbation of the pain). Results revealed that the analgesic effect was 
enhanced (doubled) in the positive information condition. Importantly, however, 
the negative information completely abolished the effect of the analgesic treat-
ment, thereby showing that negative expectations may block the efficacy of a well-
documented analgesic treatment. In line with this, a systematic review showed a 
high incidence of adverse events in placebo treated groups of anti-migraine clini-
cal trials (Amanzio, Corazzini, Vase & Benedetti 2009). Noteworthy, the adverse 
events experienced in different placebo arms corresponded to the adverse events 
produced by the actual drug against which the placebo was compared. Hence, 
adverse events may at least partially be a result of the information given in infor-
med consent procedures about such events. Taken together, these findings show 
that patients’ negative perception of a treatment may also lead to negative effects. 
Hence, it seems important for healthcare providers to try to shape for example 
expectations in a positive way. Unfortunately, in clinical practice, optimizing pa-
tients’ expectations is often complicated as verbal suggestions and information 
sheets are primarily focused on negative information and fail to discuss positive 
treatment outcome in an equally clear manner (Klinger & Flor 2013). In addition, 
observations in the United States show that 50 percent of all patients leave office 
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visits without an adequate understanding of what the physician has told them 
(Bodenheimer 2008). Hence, negative or uncertain information may reduce or 
block the placebo component of a treatment and thereby contribute to poor treat-
ment outcome. 
Most studies have only investigated placebo effects in short-term studies and 
it has been assumed that the placebo effect is brief. Yet, recent studies indicate 
that the placebo effect may be long lasting and this is especially important for 
chronic pain patients. For example, in a study by Vase and colleagues (2005) tem-
poral changes in the placebo effect and in psychological variables were examined. 
Results showed that the magnitude of the placebo effect increased during the 40 
min of investigation and this change was partly explained by a decrease in psy-
chological factors such as expectations, desire and emotions. In addition, place-
bo-controlled clinical trials of acupuncture in different painful conditions have 
shown that both active and placebo acupuncture can lead to marked symptom 
improvement lasting up to 6 months even in the placebo-treated patients, thereby 
suggesting that placebo effects maintain over long periods (Brinkhaus et al. 2006; 
Linde et al. 2005, 2007; Melchart et al. 2005; Witt et al. 2005). Thus, there is reason 
to believe that placebo effects can last for longer periods and factors like emotions, 
motivation, expectancy and previous treatment history appear to be central in the 
maintenance of these effects (Hyland 2011; Hyland, Geraghty, Joy & Turner 2006; 
Hyland & Whalley 2008; Hyland, Whalley & Geraghty 2007; Klinger & Flor 2013; 
Klinger, Soost, Flor & Worm 2007; Petersen et al. 2014; Vase, Robinson, Verne & 
Price 2005). Still, more research is needed to understand the long-term develop-
ment of placebo effects and the mechanisms involved.   
Overall the literature reviewed in this article suggests that psychosocial pla-
cebo components can interact with neurobiological factors and thereby contribute 
to the efficacy of standard pain treatments. Therefore, it may be very helpful for 
practitioners to be aware of how placebo components may either enhance or redu-
ce the outcome of active treatment effects in chronic pain patients. By establishing 
a warm and empathic patient-practitioner relationship and by directly asking pa-
tients about expectations and emotions in an attempt to optimize them in a rea-
listic manner, practitioners may have the opportunity to influence and optimize 
treatment outcome. 
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